Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2007

View Archived Issues

Sunesis Pharmaceuticals reports recent data on two lead compounds

Therapeutic silencing of mutant huntingtin in transgenic HD mice yields promising results

Gene-Activated human glucocerebrosidase active and safe in Gaucher's disease

Transition reports update on diabetes program

Phase I studies delineate pharmacokinetics of elvitegravir in healthy volunteers

Etanercept ineffective in severe asthma

Exelixis has numerous poster presentations at AACR-NCI-EORTC conference

New therapeutic agents for gastrointestinal disorders reported in recent patents

Preclinical data provide detail on the mechanism of action of trodusquemine

Arformoterol pharmacokinetics, QTc effects and dosing variability examined

Osteologix reports positive top-line results from STRONG clinical trial of NB-S101

MDV-3100 demonstrates reductions in prostate-specific antigen in phase I/II trial

AstraZeneca secures option for exclusive license to Targacept's TC-5619

Derma acquires licensing contract for DSC-127 from the University of Southern California

Epix identifies three lead candidates in G-protein-coupled receptor discovery program

FDA to review Abbott's premarket approval submission for Xience V

Clinical study supports expanded indication of BioThrax for post-exposure prophylaxis

Novacea ends ASCENT-2 trial of Asentar for androgen-independent prostate cancer

New antipsychotic agents emerge from GlaxoSmithKline R&D

GSK initiates ENABLE 1 and ENABLE 2 phase III trials of eltrombopag

IntelGenx and Cary Pharmaceuticals enter definitive agreement for CPI-300 antidepressant

CombinatoRx initiates phase IIa clinical trial of CRx-191 for psoriasis

Poniard reports positive preliminary data from ongoing phase I trial of oral picoplatin

Locus signs second research agreement with Ono for preclinical kinase drug candidates

MacroChem reports positive interim data from phase II study of EcoNail

Systemically administered calpain inhibitor effective in animal models of SAH

Dual H3 antagonist/SERT inhibitor in development at J&J for depression

Abbott characterizes novel analgesic CB2 receptor agonist

In vitro and in vivo activity of new 5-HT2C inverse agonist characterized in San Diego

FDA approves Abilify for adolescent patients aged 13-17 years with schizophrenia

STEP study confirms Merck & Co.'s investigational HIV vaccine V-520 was not effective

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...